ECOR
electroCore, Inc.
NASDAQ · Healthcare · Medical - Devices · US
$8.16
+12.86%Oct 29, 2026, 12:00 UTC
electroCore announced that it will report financial results for the third quarter ended September 30, 2026, after the market closes on November 4, 2026.
Source:Oct 28, 2026, 12:00 UTC
electroCore submitted a 510(k) premarket notification to the U.S. Food and Drug Administration seeking clearance of its Quell wearable neuromodulation platform to treat chronic chemotherapy-induced peripheral neuropathy.
Source:Sep 9, 2026, 12:32 UTC
Mike Fox was appointed Co-Chief Executive Officer and member of the Board of Directors of electroCore, Inc., effective September 8, 2026.
Aug 7, 2026, 00:12 UTC
electroCore, Inc. reported a second-quarter loss of $0.33 per share, beating the Zacks Consensus Estimate of a loss of $0.41 and improving from a loss of $0.35 per share a year ago.